# Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

Source: https://onco.cc/trials/nct05222555/  
OnCo record `nct05222555` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Corporation, active and no longer recruiting.

## Summary

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients is a phase 1/2 interventional study registered as NCT05222555 by Incyte Corporation, with 53 participants enrolled, started 2022-07-19 and due to reach its primary completion in 2024-07-17. Interventions recorded: Tafasitamab, Lenalidomide. Conditions listed: Diffuse Large B Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05222555
- Phase: 1/2
- Setting: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Sponsor: Incyte Corporation
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT05222555: https://clinicaltrials.gov/study/NCT05222555

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct05222555.json